المؤلفون: Jones, R.L. (Robin L.), Ratain, M.J. (Mark), O'Dwyer, P.J. (Peter J.), Siu, R.K. (Ronald), Jassem, J., Medioni, J. (Jacques), DeJonge, M.J.A. (Maja J.), Rudin, C.M. (Charles), Sawyer, M. (Michael), Khayat, D. (David), Awada, A. (Ahmad), de Vos-Geelen, J. (Judith), Evans, T.R.J. (Jeffry), Obel, J. (Jennifer), Brockstein, B. (Bruce), DeGreve, J. (Jacques), Baurain, J.F., Maki, R.G. (Robert G.), D'Adamo, D. (David), Dickson, M.A. (Mark A.), Undevia, S. (Samir), Geary, D. (David), Janisch, L. (Linda), Bedard, P.L. (Philippe L.), Abdul Razak, A.R. (Albiruni R.), Kristeleit, R.S. (R.), Vitfell-Rasmussen, J. (Joanna), Walters, I. (Ian), Kaye, S.B. (Stan B.), Schwartz, G. (Gary)

المصدر: European Journal of Cancer vol. 120, pp. 132-139

مصطلحات موضوعية: Brivanib, FGF2 status, Ovarian cancer, Randomised discontinuation trial, Sarcomas, Solid tumours

وصف الملف: application/pdf

Relation: http://repub.eur.nl/pub/119604; urn:hdl:1765/119604

الاتاحة: http://repub.eur.nl/pub/119604
https://doi.org/10.1016/j.ejca.2019.07.024